Edgar Filing: Sarepta Therapeutics, Inc. - Form 4

Sarepta Thera	peutics, Inc.										
Form 4											
June 06, 2013											
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION								OMB APPROVAL			
	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549						COMMISSION	OMB Number:	3235-0287		
Check this if no longe								Expires: Ja	January 31 2005		
subject to	subject to STATEMENT OF CHANGE					CIA	LOW	NERSHIP OF	Estimated a	Estimated average	
Section 16 Form 4 or	j.	SECURITIES								burden hours per	
Form 5	Filed pur	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,							response	0.5	
obligation	⁸ Section 170							f 1935 or Sectio	n		
may contin See Instruc	nue.			vestment (•						
1(b).											
(Print or Type Ro	esponses)										
Carlahaa William Aldan			2. Issuer Symbol	Issuer Name and Ticker or Trading				5. Relationship of Reporting Person(s) to Issuer			
Symbol				pta Therapeutics, Inc. [SRPT]							
(Last)	(First) (N		•	•		[011]	-1	(Chec	ck all applicable	e)	
215 FIRST STREET, SUITE 7 (Month/ (Street) 4. If Am				ate of Earliest Transaction onth/Day/Year)				_X_ Director10% Owner			
			06/04/2013					Delow) Officer (give title below) Other (specify below)			
			4. If Amer	f Amendment, Date Original d(Month/Day/Year)				6. Individual or Joint/Group Filing(Check			
			Filed(Mont					Applicable Line) _X_ Form filed by One Reporting Person			
CAMBRIDG	E, MA 02412								More than One Re		
(City)	(State)	(Zip)	Table	e I - Non-Do	erivative S	ecuri	ties Ac	quired, Disposed of	f, or Beneficial	lly Owned	
1.Title of	2. Transaction Dat	e 2A. Deen	ned	3.	4. Securit	ties		5. Amount of	6. Ownership	7. Nature of	
			on Date, if TransactionAcquired (A) or						Form: Direct	Indirect	
(Instr. 3)		CodeDisposed of (D)Day/Year)(Instr. 8)(Instr. 3, 4 and 5)			Beneficially Owned	(D) or Indirect (I)	Beneficial Ownership				
		(WORLD)	Jay/Tear)	(IIIsu: 0)	(msu. 5,	+ anu	5)	Following	(Instr. 4)	(Instr. 4)	
						(A)		Reported			
						or		Transaction(s) (Instr. 3 and 4)			
Common				Code V	Amount 1,000	(D)	Price				
Stock (1)	06/04/2013			А	(2)	А	\$0	5,166	D		
					_						

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactiorDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Ar Underlying Se (Instr. 3 and 4)
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title 2
Non-Qualified Stock Option (right to buy)	\$ 34.92	06/04/2013		А	20,000	06/04/2014 <u>(3)</u>	06/04/2023	Common Stock (1)

Edgar Filing: Sarepta Therapeutics, Inc. - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Goolsbee William Alden 215 FIRST STREET, SUITE 7 CAMBRIDGE, MA 02412	Х						
Signatures							
By: David Tyronne Howton For Goolsbee	: William	Alden		06/06/2013			

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

On June 6, 2013, Sarepta Therapeutics, Inc., a Delaware corporation, became the successor of Sarepta Therapeutics, Inc., an Oregon
 (1) corporation, pursuant to a merger. The merger had the effect of changing the state of incorporation of Sarepta Therapeutics, Inc. from Oregon to Delaware, but did not alter the proportionate interests of security holders.

(2) Grant of restricted stock, which shall vest in full on the anniversary date of the grant.

(3) This option will vest at a rate of 25% annually over four years beginning on the first anniversary of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.